Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2005
11/16/2005CN1227265C Antibodies to CCR5
11/16/2005CN1227035C Conjugates and method for production thereof, and their use for transporting molecules via biological membranes
11/16/2005CN1227033C Method of treating cancer with anti-neurotrophin agents
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6965010 Polypeptideeptide for use in the treatment of cancer, neovascularization defects, retinopathies, arthritis and psoraisis
11/15/2005US6964968 Respiratory system disorders; cardiovascular disorders; viricides
11/15/2005US6964951 Polynucleotide
11/15/2005US6964950 Oligonucleotides which hybridize with nucleic acids which encode said protein; gene therapy; genetic engineering; for treatment of angina and myocardial infarction
11/15/2005US6964853 Smad6 and uses thereof
11/15/2005US6964845 Thermostable phage lambda operator mutants for regulating gene expression
11/10/2005WO2005106493A1 Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
11/10/2005WO2005106473A1 Method of screening therapeutic agent for neurodegenerative disease
11/10/2005WO2005106021A1 Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8)
11/10/2005WO2005105998A1 HUMAN ANTIAMYLOID β PEPTIDE ANTIBODY AND ANTIBODY FRAGMENT THEREOF
11/10/2005WO2005105997A1 Connexin 40 tissue specific gene mutations
11/10/2005WO2005105996A1 A pax-encoding vector and use thereof
11/10/2005WO2005105987A1 Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 2 (csnk1d iso 2)
11/10/2005WO2005105833A2 Novel herpes simplex viruses and uses thereof
11/10/2005WO2005105157A2 INHIBITION OF HAIRLESS PROTEIN mRNA
11/10/2005WO2005105156A1 Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
11/10/2005WO2005105155A1 Methods for delivering a gene product to the eye
11/10/2005WO2005105136A1 Nanogene therapy for cell proliferation disorders
11/10/2005WO2005105130A1 Novel therapeutic usage of factor derived from pigment epithelium, capable of inhibiting nadph oxidase activity
11/10/2005WO2005033313A3 Intracelluar trapping of radionuclides by enzyme-mediated reduction
11/10/2005WO2005030259A3 Nucleic acid-lipophilic conjugates
11/10/2005US20050251873 Ace2 activation for treatment of heart, lung and kidney disease and hypertension
11/10/2005US20050251871 Novel ubiquitin ligases as therapeutic targets
11/10/2005US20050250725 Regulation of the P21 gene and uses thereof
11/10/2005US20050250724 Methods for preventing or reducing ischemia/reperfusion induced myocardial cell death
11/10/2005US20050250722 FcgammaRIIA-specific nucleic acid interference
11/10/2005US20050250721 A replication-defective adenoviral or adeno-associated viral vector; gene therapy for congestive heart failure
11/10/2005US20050250720 Novel compound
11/10/2005US20050250718 Pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity
11/10/2005US20050250717 Chromatin remodeling protein as a marker expressed by stromal progenitor cells
11/10/2005US20050250716 Immunostimulatory oligodeoxynucleotides
11/10/2005US20050250695 Combination PDGF, KGF, IGF, and IGFBP for wound healing
11/10/2005US20050250688 Adding to blood a deactivated, genetic engineered mutein; anticoagulants
11/10/2005US20050250207 Retrons for gene targeting
11/10/2005US20050250203 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
11/10/2005US20050250185 OGH fusion polypeptides and therapeutic uses thereof
11/10/2005US20050250160 Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
11/10/2005US20050250153 Novel fetal genes
11/10/2005US20050250150 outer membrane proteins (OMPs) that, alone or in combination, are capable of inducing protective immunity against Lawsonia intracellularis bacteria
11/10/2005US20050250143 MEKK1-interacting FHA protein 1 (MIF1)
11/10/2005US20050250123 Reducing galectin-12 activity to reduce formation of adipocytes
11/10/2005US20050250106 Gene knock-down by intracellular expression of aptamers
11/10/2005US20050250102 Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1
11/10/2005US20050249794 Compositions for stimulating cytokine secretion and inducing an immune response
11/10/2005US20050249786 Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
11/10/2005US20050249748 Polypeptides; antigens; vaccines; fusion protein containing signal peptide and polypeptide; genetic engineered Listeria bacteria
11/10/2005US20050249721 Compositions and methods for targeted biological delivery of molecular carriers
11/10/2005US20050249718 Compositions and methods for treating disorders associated with abnormal phosphate metabolism
11/10/2005US20050249707 Stimulating an immune response in human or animal, by administering a gene, infected DENDRITIC CELLS; without preventing antigen processing occurring within the infected cell; increase gene expression on the surface of tumour cells; protection against cancer; vaccines
11/10/2005US20050249706 Using transgenic and attenuated salmonella comprising tumor modulatory proteins and pharmceutical conjugate to treat cell proliferative disorders; targeted tissue therapy
11/10/2005US20050249670 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
11/10/2005US20050249663 Coadministration of transport protein with conjugated cobalamin to deliver agents
11/10/2005DE10006033B4 Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen Immunizing an individual against carcinomas and their precursors
11/10/2005CA2565410A1 Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
11/10/2005CA2564432A1 Human anti-amyloid .beta. peptide antibody and fragment of said antibody
11/10/2005CA2557532A1 Inhibition of hairless protein mrna
11/09/2005EP1593742A2 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
11/09/2005EP1592808A2 Single nucleotide polymorphisms as predictive diagnostics for adverse drug reactions (adr) and drug efficacy
11/09/2005EP1592800A2 Mesecnhymal stem cells as a vehicle for ion channel transfer in syncytial structures
11/09/2005EP1592795A2 Oligomeric compounds for the modulation of ras expression
11/09/2005EP1592789A2 Administration of transposon-based vectors to reproductive organs
11/09/2005EP1592709A2 Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
11/09/2005EP1592702A2 Beta-2 microglobulin (b2m) and b2m related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
11/09/2005EP1592455A2 Herpesvirus amplicon particles
11/09/2005EP1592454A1 Tarp promoter and uses thereof
11/09/2005EP1592391A2 Tra16 a tr4/tr2 repressor
11/09/2005EP1592385A2 Lactate dehydrogenase as a novel target and reagent for diabetes therapy
11/09/2005EP1287142B1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
11/09/2005EP1246930B1 Replication incompetent herpes virus vectors
11/09/2005EP1220932B1 Human carboxypeptidases and polynucleotides encoding the same
11/09/2005EP1212421B1 Gas1 polypeptides
11/09/2005EP1206542B1 Replication protein a binding transcriptional factor (rbt1) and uses thereof
11/09/2005EP1204321B1 Super-active porcine growth hormone releasing hormone analog
11/09/2005EP1154692B1 A method of controlling fungal pathogens, and agents useful for same
11/09/2005EP1141245B1 Somatic cells with ablated prp gene and methods of use
11/09/2005EP1111048B1 Neutral amino acid transporter and gene thereof
11/09/2005EP0960192B1 Synthetic polynucleotides
11/09/2005EP0928290B9 Oligoribonucleotides and ribonucleases for cleaving rna
11/09/2005EP0910644B1 Retinoid metabolizing protein
11/09/2005EP0904380B1 Synthetic hiv genes
11/09/2005EP0772455B1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy
11/09/2005EP0753068B1 Ligands added to adenovirus fiber
11/09/2005EP0751992B1 Vascular endothelial growth factor 2
11/09/2005EP0750457B1 Targeted cytolysis of hiv-infected cells by chimeric cd4 receptor-bearing cells
11/09/2005CN1695059A Method of diagnosing colon and gastric cancers
11/09/2005CN1694900A EE3-protein family and corresponding DNA sequences
11/09/2005CN1694736A Medical devices containing rapamycin analogs
11/09/2005CN1694721A Nucleic acid coated particles
11/09/2005CN1694714A Formulation for inwardly transferring nucleic acids into eucaryotic cells
11/09/2005CN1694490A Method, equipment and computer program of changed digital color image
11/09/2005CN1692946A Method for cnotrolling cell fector expression by heating, and its application for treating tumor
11/09/2005CN1692945A Anti-disease prepn. contg. piginterleukin-4,6 fused gene
11/09/2005CN1692944A Prepn. and application of nanometer molecule prepn. with fused immunity pig gene used for anti-infection
11/09/2005CN1692943A Preparation and application of CpG DNA molecule anti-infection and immunity prepn
11/09/2005CN1692942A Prepn. and application tech. for pig interleukin-4 gene anti-diseases prepns.
11/09/2005CN1692941A Prepn. and application of pig interleukin-6 gene anti-infection immunopotentiator
1 ... 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 ... 870